Cardiff Oncology, Inc. (CRDF) Stock Price & Analysis
Cardiff Oncology, Inc. (CRDF) closed at USD 0.97 on Thursday, October 15, 2026, down 0.25% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.97; the Oct 15, 2026 session ranged USD 0.95–1 on volume of 453,812 shares. Market capitalization is $75.54M, with a 52-week range of USD 0.76–3.31 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRDF.md
Key facts (CRDF)
- Analysts: Buy (mean 2.33 on a 1–5 scale) (6 analysts), mean target USD 5.81 (range 1.2–12).
- Total return with dividends: 1Y -56.7% vs S&P 500 +18.1%; 5Y -84.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.13, revenue estimate $86K.
Analysts (CRDF)
Consensus Buy (mean 2.33 on a 1–5 scale), 6 analysts; mean target USD 5.81 (low 1.2, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-15 | HC Wainwright & Co. | Upgrade | Neutral → Buy | $9 |
| 2026-08-12 | William Blair | Downgrade | Outperform → Market Perform |
Total return (dividends reinvested) (CRDF)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -56.7% | -84.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -56.8% | -31.4% |
| Volatility (annualized) | 91.4% | 95.6% |
| Max drawdown | -74.8% (Jan 2026→Jul 2026) | -87.9% (Jan 2022→Jul 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 0.97 |
|---|---|
| Change | ▼ 0.25% (down) |
| Previous Close | USD 0.97 |
| Open | USD 0.95 |
| Day Range | USD 0.95 – 1 |
| 52-Week Range | USD 0.76 – 3.31 |
| Volume | 453,812 shares |
| Market Cap | $75.54M |
| Exchange | NCM |
Technical Analysis (CRDF)
Nexqual's technical model rates CRDF "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 38.6 (neutral) |
| vs SMA50 | Below (USD 1.09) |
| MACD | -0.04 (negative) |
Analyst Ratings (CRDF)
Wall Street analysts rate CRDF "Buy" based on 6 analysts, with a mean price target of USD 5.81 (range USD 1.2–12), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 5.81 |
| High Target | USD 12 |
| Low Target | USD 1.2 |
| Buy / Hold / Sell | 3 / 3 / 0 |
Earnings (CRDF)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $86,430 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.14 vs est -0.16 ▲ beat |
| 2026-03-31 | USD -0.18 vs est -0.12 ▼ miss |
| 2025-12-31 | USD -0.11 vs est -0.2 ▲ beat |
| 2025-09-30 | USD -0.17 vs est -0.21 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (CRDF)
| Total Revenue | $508,000 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -14.10% |
| Gross Margin | +0.00% |
| Operating Margin | -9245.19% |
| Profit Margin | +0.00% |
| ROE | -94.08% |
| Debt / Equity | 0.02 |
| Current Ratio | 3.3 |
| Total Cash | $34.52M |
| Total Debt | $457,000 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (CRDF)
Nexqual rates Cardiff Oncology, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Critical — Revenue -13% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $35M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$41M (TTM) |
| Efficiency | Critical — ROE -94%, ROA -46.7% |
Ownership (CRDF)
| Insider Ownership | +6.20% |
|---|---|
| Institutional Ownership | +22.11% |
| Shares Outstanding | 77.80M |
| Float | 75.38M |
| Short % of Float | +15.85% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (CRDF)
Cardiff Oncology, Inc. is led by Mani Mohindru (age 53), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| President, CEO & Director | Mani Mohindru (age 53) |
|---|---|
| Chief Financial Officer | Joshua Muntner BFA (age 56) |
| Chief Operating Officer | Ajay Aggarwal |
| Chief Scientific Officer | Tod Smeal (age 60) |
Major Backers & Investors (CRDF)
Notable institutional backers of Cardiff Oncology, Inc. include Laurion Capital Management, LP, Pfizer Inc, Franklin Resources, Inc., according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Laurion Capital Management, LP | 3.98% |
| Pfizer Inc | 3.1% |
| Franklin Resources, Inc. | 1.55% |
| BLAIR WILLIAM & CO/IL | 1.17% |
| GoalVest Advisory, LLC | 0.88% |
| UBS Group AG | 0.82% |
| Jane Street Group, LLC | 0.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.87% |
| BlackRock | 1.53% |
| Geode Capital | 1.05% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt